Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Immunosurveillance and therapy of multiple myeloma are CD226 dependent
Camille Guillerey, … , Mark J. Smyth, Ludovic Martinet
Camille Guillerey, … , Mark J. Smyth, Ludovic Martinet
Published April 20, 2015
Citation Information: J Clin Invest. 2015;125(5):2077-2089. https://doi.org/10.1172/JCI77181.
View: Text | PDF | Corrigendum
Research Article Immunology Oncology Article has an altmetric score of 24

Immunosurveillance and therapy of multiple myeloma are CD226 dependent

  • Text
  • PDF
Abstract

Multiple myeloma (MM) is an age-dependent hematological malignancy. Evaluation of immune interactions that drive MM relies on in vitro experiments that do not reflect the complex cellular stroma involved in MM pathogenesis. Here we used Vk*MYC transgenic mice, which spontaneously develop MM, and demonstrated that the immune system plays a critical role in the control of MM progression and the response to treatment. We monitored Vk*MYC mice that had been crossed with Cd226 mutant mice over a period of 3 years and found that CD226 limits spontaneous MM development. The CD226-dependent anti-myeloma immune response against transplanted Vk*MYC MM cells was mediated both by NK and CD8+ T cells through perforin and IFN-γ pathways. Moreover, CD226 expression was required for optimal antimyeloma efficacy of cyclophosphamide (CTX) and bortezomib (Btz), which are both standardly used to manage MM in patients. Activation of costimulatory receptor CD137 with mAb (4-1BB) exerted strong antimyeloma activity, while inhibition of coinhibitory receptors PD-1 and CTLA-4 had no effect. Taken together, the results of this study provide in vivo evidence that CD226 is important for MM immunosurveillance and indicate that specific immune components should be targeted for optimal MM treatment efficacy. As progressive immunosuppression associates with MM development, strategies aimed to increase immune functions may have important therapeutic implications in MM.

Authors

Camille Guillerey, Lucas Ferrari de Andrade, Slavica Vuckovic, Kim Miles, Shin Foong Ngiow, Michelle C.R. Yong, Michele W.L. Teng, Marco Colonna, David S. Ritchie, Martha Chesi, P. Leif Bergsagel, Geoffrey R. Hill, Mark J. Smyth, Ludovic Martinet

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 Total
Citations: 3 8 6 8 10 11 7 7 6 7 4 77
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (77)

Title and authors Publication Year
Depletion of myeloid-derived suppressor cells sensitizes murine multiple myeloma to PD-1 checkpoint inhibitors
Xiong W, Xiao L, Duan R, Wang Q, Xian M, Zhang C, Su P, LI Y, Zhong L, Qian J, Zheng C, Yi Q
Journal for Immunotherapy of Cancer 2025
One-carbon metabolism is distinct metabolic signature for proliferative intermediate exhausted T cells of ICB-resistant cancer patients
Park YC, Hwang Y, Jeong JW, Lee CM, Kim M, Jo S, Joo S, Hwang N, Fang S
Cell Death Discovery 2025
Polyfunctional CD8(+)CD226(+)RUNX2(hi) effector T cells are diminished in advanced stages of chronic lymphocytic leukemia.
Rezaeifar M, Shahbaz S, Peters AC, Gibson SB, Elahi S
Molecular oncology 2025
The role of exhausted natural killer cells in the immunopathogenesis and treatment of leukemia
Barshidi A, Ardeshiri K, Ebrahimi F, Alian F, Shekarchi AA, Hojjat-Farsangi M, Jadidi-Niaragh F
Cell communication and signaling : CCS 2024
Diet-induced obesity reduces bone marrow T and B cells and promotes tumor progression in a transplantable Vk*MYC model of multiple myeloma
Nedal TM, Moen SH, Roseth IA, Tryggestad SS, Aass KR, Hov GG, Hella H, Sponaas AM, Standal T
Scientific Reports 2024
HLA class I NK-epitopes and KIR diversities in patients with multiple myeloma.
Beelen NA, Molenbroeck SJJ, Groeneveld L, Voorter CE, Bos GMJ, Wieten L
Immunogenetics 2024
Tumor-induced natural killer cell dysfunction is a rapid and reversible process uncoupled from the expression of immune checkpoints
Pouxvielh K, Marotel M, Drouillard A, Villard M, Moreews M, Bossan A, Poiget M, Khoryati L, Benezech S, Fallone L, Hamada S, Rousseaux N, Picq L, Rocca Y, Berton A, Teixeira M, Mathieu AL, Ainouze M, Hasan U, Fournier A, Thaunat O, Marçais A, Walzer T
Science Advances 2024
Immune microenvironment in papillary thyroid carcinoma: roles of immune cells and checkpoints in disease progression and therapeutic implications
Zheng X, Sun R, Wei T
Frontiers in Immunology 2024
Next-Generation Therapies for Multiple Myeloma
Meermeier EW, Bergsagel PL, Chesi M
Annual review of cancer biology 2024
Interferon gamma‐mediated prevention of tumor progression in a mouse model of multiple myeloma
Kellermayer Z, Tahri S, de Jong MM, Papazian N, Fokkema C, Stoetman EC, Hoogenboezem R, van Beek G, Sanders MA, Boon L, Den Hollander C, Broijl A, Sonneveld P, Cupedo T
HemaSphere 2024
The multifaceted role of SMAD4 in immune cell function
Cui X, Song Y, Han J, Yuan Z
Biochemistry and Biophysics Reports 2024
The pathogenetic significance of exhausted T cells in a mouse model of mature B cell neoplasms.
Shibamiya A, Miyamoto-Nagai Y, Koide S, Oshima M, Rizq O, Aoyama K, Nakajima-Takagi Y, Kato R, Kayamori K, Isshiki Y, Oshima-Hasegawa N, Muto T, Tsukamoto S, Takeda Y, Koyama-Nasu R, Chiba T, Honda H, Yokote K, Iwama A, Sakaida E, Mimura N
Cancer Immunology, Immunotherapy 2023
Adoptive Immunotherapy and High-Risk Myeloma
Duane C, O\u2019Dwyer M, Glavey S
Cancers 2023
NEDD8-activating enzyme inhibition potentiates the anti-myeloma activity of natural killer cells
Petillo S, Sproviero E, Loconte L, Cuollo L, Zingoni A, Molfetta R, Fionda C, Soriani A, Cerboni C, Petrucci MT, Fazio F, Paolini R, Santoni A, Cippitelli M
Cell Death and Disease 2023
Dysregulation of DNAM-1-Mediated NK Cell Anti-Cancer Responses in the Tumor Microenvironment
Paolini R, Molfetta R
Cancers 2023
TCR-independent CD137 (4–1BB) signaling promotes CD8+-exhausted T cell proliferation and terminal differentiation
Pichler AC, Carrié N, Cuisinier M, Ghazali S, Voisin A, Axisa PP, Tosolini M, Mazzotti C, Golec DP, Maheo S, do Souto L, Ekren R, Blanquart E, Lemaitre L, Feliu V, Joubert MV, Cannons JL, Guillerey C, Avet-Loiseau H, Watts TH, Salomon BL, Joffre O, Grinberg-Bleyer Y, Schwartzberg PL, Lucca LE, Martinet L
Immunity 2023
IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma
Pisano MD, Sun F, Cheng Y, Parashar D, Zhou V, Jing X, Sompallae R, Abrudan J, Zimmermann MT, Mathison A, Janz S, Pufall MA
Haematologica 2023
MICA/B antibody induces macrophage-mediated immunity against acute myeloid leukemia
P da Silva, S Xing, A Kotini, E Papapetrou, X Song, K Wucherpfennig, J Mascarenhas, L de Andrade
Blood 2022
The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value
V Desantis, F Savino, A Scaringella, M Potenza, C Nacci, M Frassanito, A Vacca, M Montagnani
Journal of Clinical Medicine 2022
The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches
I Lagreca, G Riva, V Nasillo, P Barozzi, I Castelli, S Basso, F Bettelli, D Giusti, A Cuoghi, P Bresciani, A Messerotti, A Gilioli, V Pioli, C Colasante, D Vallerini, A Paolini, M Maccaferri, F Donatelli, F Forghieri, M Morselli, E Colaci, G Leonardi, R Marasca, L Potenza, R Manfredini, E Tagliafico, T Trenti, P Comoli, M Luppi
International journal of molecular sciences 2022
The Road Less Taken: Less Appreciated Pathways for Manipulating CD8+ T Cell Exhaustion
Pichler AC, Cannons JL, Schwartzberg PL
Frontiers in immunology 2022
Innate lymphoid cells in early tumor development
Warner K, Ghaedi M, Chung DC, Jacquelot N, Ohashi PS
Frontiers in immunology 2022
Cowpea Mosaic Virus and Natural Killer Cell Agonism for In Situ Cancer Vaccination
Koellhoffer EC, Steinmetz NF
Nano letters 2022
Extracellular Vesicles in Multiple Myeloma—Cracking the Code to a Better Understanding of the Disease
Iskrzak J, Zygmunciak P, Misiewicz-Krzemińska I, Puła B
Cancers 2022
The immune system in multiple myeloma and precursor states: lessons and implications for immunotherapy and interception
Dhodapkar MV
American Journal of Hematology 2022
Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression
J Dahlhoff, H Manz, T Steinfatt, J Delgado-Tascon, E Seebacher, T Schneider, A Wilnit, Z Mokhtari, P Tabares, D Böckle, L Rasche, KM Kortüm, MB Lutz, H Einsele, A Brandl, A Beilhack
Leukemia 2021
Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention
SS McCachren, KM Dhodapkar, MV Dhodapkar
Frontiers in immunology 2021
Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
SA Minnie, GR Hill
Frontiers in immunology 2021
Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings?
M Lionetti, MC Vià, F Albano, A Neri, N Bolli, P Musto
Cancers 2021
The Cancer-Immunity Cycle in Multiple Myeloma
M Casey, K Nakamura
ImmunoTargets and Therapy 2021
Regulatory T-Cells and Multiple Myeloma: Implications in Tumor Immune Biology and Treatment
C Hadjiaggelidou, E Katodritou
Journal of Clinical Medicine 2021
Expression of NK Cell Receptor Ligands on Leukemic Cells Is Associated with the Outcome of Childhood Acute Leukemia
MV Martínez-Sánchez, JL Fuster, JA Campillo, AM Galera, M Bermúdez-Cortés, ME Llinares, E Ramos-Elbal, JF Pascual-Gázquez, AM Fita, H Martínez-Banaclocha, JA Galián, L Gimeno, M Muro, A Minguela
Cancers 2021
CD8+ T lymphocytes are sensitive to NKG2A/HLA-E licensing interaction: role in the survival of cancer patients
L Gimeno, I González-Lozano, MF Soto-Ramírez, MV Martínez-Sánchez, P López-Cubillana, JL Fuster, J Martínez-García, J Martínez-Escribano, JA Campillo, E Pons-Fuster, B Ferri, A López-Abad, M Muro, A Minguela
OncoImmunology 2021
Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma
T Pazina, AW MacFarlane, L Bernabei, E Dulaimi, R Kotcher, C Yam, NA Bezman, MD Robbins, EA Ross, KS Campbell, AD Cohen
Cancers 2021
Harnessing the Immune System to Fight Multiple Myeloma
J Krejcik, MB Barnkob, CG Nyvold, TS Larsen, T Barington, N Abildgaard
Cancers 2021
Immunotherapy of multiple myeloma
Simone A. Minnie, Geoffrey R Hill
Journal of Clinical Investigation 2020
CD226 deletion improves post-infarction healing via modulating macrophage polarization in mice
J Li, Y Song, JY Jin, GH Li, YZ Guo, HY Yi, JR Zhang, YJ Lu, JL Zhang, CY Li, C Gao, L Yang, F Fu, F Chen, SM Zhang, M Jia, GX Zheng, JM Pei, LH Chen
Theranostics 2020
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
Y Cao, X Wang, T Jin, Y Tian, C Dai, C Widarma, R Song, F Xu
Signal Transduction and Targeted Therapy 2020
Immune-infiltration based signature as a novel prognostic biomarker in gastrointestinal stromal tumour
ZW Wei, J Wu, WB Huang, J Li, XF Lu, YJ Yuan, WJ Xiong, XH Zhang, W Wang, YL He, CH Zhang
EBioMedicine 2020
Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy
S Jeong, SH Park
Immune Network 2020
The Role of Natural Killer (NK) Cells in Acute Coronary Syndrome: A Comprehensive Review
M Kumrić, TT Kurir, JA Borovac, J Božić
Biomolecules 2020
Natural Killer Cells: Tumor Surveillance and Signaling
LG Guzman, N Keating, SE Nicholson
Cancers 2020
CD155: A Multi-Functional Molecule in Tumor Progression
R Molfetta, B Zitti, M Lecce, ND Milito, H Stabile, C Fionda, M Cippitelli, A Gismondi, A Santoni, R Paolini
International journal of molecular sciences 2020
Development of CAR-T cell therapies for multiple myeloma
N Gagelmann, K Riecken, C Wolschke, C Berger, FA Ayuk, B Fehse, N Kröger
Leukemia 2020
NK Cell-Based Immune Checkpoint Inhibition
M Khan, S Arooj, H Wang
Frontiers in immunology 2020
Extracellular Vesicles Orchestrate Immune and Tumor Interaction Networks
KH Yim, AA Hrout, S Borgoni, R Chahwan
Cancers 2020
Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model
Camille Guillerey, Kyohei Nakamura, Andrea C Pichler, Deborah Barkauskas, Sophie Krumeich, Kimberley Stannard, Kim Miles, Heidi Harjunpää, Yuan Yu, Mika Casey, alina doban, Mircea Lazar, Gunter Hartel, David Smith, Slavica Vuckovic, Michele Teng, P Leif Bergsagel, Marta Chesi, Geoffrey R Hill, Ludovic Martinet, Mark Smyth
JCI Insight 2019
CD96 Is an Immune Checkpoint That Regulates CD8 + T-cell Antitumor Function
D Mittal, A Lepletier, J Madore, AR Aguilera, K Stannard, SJ Blake, VL Whitehall, C Liu, ML Bettington, K Takeda, GV Long, RA Scolyer, R Lan, N Siemers, A Korman, MW Teng, RJ Johnston, WC Dougall, MJ Smyth
Cancer immunology research 2019
TIGIT as an emerging immune checkpoint
H Harjunpää, C Guillerey
Clinical & Experimental Immunology 2019
Immunotherapeutics in Multiple Myeloma: How Can Translational Mouse Models Help?
RE Cooke, R Koldej, D Ritchie
Journal of Oncology 2019
Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma
AM Lesokhin, S Bal, AZ Badros
Cancer immunology research 2019
Human peripheral blood DNAM-1 neg NK cells are a terminally differentiated subset with limited effector functions
KA Stannard, S Lemoine, NJ Waterhouse, F Vari, L Chatenoud, MK Gandhi, L Martinet, MJ Smyth, C Guillerey
Blood Advances 2019
Natural Killer Cell Recruitment and Activation Are Regulated by CD47 Expression in the Tumor Microenvironment
PR Nath, D Pal-Nath, A Mandal, MC Cam, AL Schwartz, DD Roberts
Cancer immunology research 2019
Blocking IFNRA1 inhibits multiple myeloma-driven Treg expansion and immunosuppression
Yawara Kawano, Oksana Zavidij, Jihye Park, Michele Moschetta, Katsutoshi Kokubun, Tarek H. Mouhieddine, Salomon Manier, Yuji Mishima, Naoka Murakami, Mark Bustoros, Romanos Sklavenitis Pistofidis, Mairead Reidy, Yu J Shen, Mahshid Rahmat, Pavlo Lukyanchykov, Esilida Sula Karreci, Shokichi Tsukamoto, Jiantao Shi, Satoshi Takagi, Daisy Huynh, Antonio Sacco, Yu-Tzu Tai, Marta Chesi, P Leif Bergsagel, Aldo Roccaro, Jamil Azzi, Irene Ghobrial
Journal of Clinical Investigation 2018
CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms
Xian-Yang Li, Indrajit Das, Ailin Lepletier, Venkateswar Addala, Tobias Bald, Kimberley Stannard, Deborah Barkauskas, Jing Liu, Amelia Aguilera, Kazuyoshi Takeda, Matthias Braun, Kyohei Nakamura, Sebastien Jacquelin, Steven Lane, Michele Teng, William Dougall, Mark Smyth
Journal of Clinical Investigation 2018
Bone marrow transplantation generates T cell-dependent control of myeloma in mice
Slavica Vuckovic, Simone A. Minnie, David Smith, Kate H Gartlan, Thomas S Watkins, Kate A Markey, Pamela Mukhopadhyay, Camille Guillerey, Rachel D Kuns, Kelly Locke, Antonia L. Pritchard, Peter Johansson, Antiopi Varelias, Ping Zhang, Nicholas, D Huntington, Nicola Waddell, Marta Chesi, John J Miles, Mark Smyth, Geoffrey R Hill
Journal of Clinical Investigation 2018
CD226 regulates natural killer cell antitumor responses via phosphorylation-mediated inactivation of transcription factor FOXO1
X Du, P de Almeida, N Manieri, D de Almeida Nagata, TD Wu, KH Bowles, V Arumugam, J Schartner, R Cubas, S Mittman, V Javinal, KR Anderson, S Warming, JL Grogan, EY Chiang
Proceedings of the National Academy of Sciences 2018
One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy
L Besson, E Charrier, L Karlin, O Allatif, A Marçais, P Rouzaire, L Belmont, M Attal, C Lombard, G Salles, T Walzer, S Viel
Frontiers in immunology 2018
Checkpoint Inhibition in Myeloma: Opportunities and Challenges
F Costa, R Das, JK Bailur, K Dhodapkar, MV Dhodapkar
Frontiers in immunology 2018
Key Role of the CD56lowCD16low Natural Killer Cell Subset in the Recognition and Killing of Multiple Myeloma Cells
E Vulpis, H Stabile, A Soriani, C Fionda, M Petrucci, E Mariggio, M Ricciardi, M Cippitelli, A Gismondi, A Santoni, A Zingoni
Cancers 2018
Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs
G Pittari, L Vago, M Festuccia, C Bonini, D Mudawi, L Giaccone, B Bruno
Frontiers in immunology 2017
NK Cell Exhaustion
J Bi, Z Tian
Frontiers in immunology 2017
Trial Watch: Immunogenic cell death induction by anticancer chemotherapeutics
AD Garg, S More, N Rufo, O Mece, ML Sassano, P Agostinis, L Zitvogel, G Kroemer, L Galluzzi
OncoImmunology 2017
Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma
L Tran, CT Allen, R Xiao, E Moore, R Davis, SJ Park, K Spielbauer, CV Waes, NC Schmitt
Cancer immunology research 2017
Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis
EM Putz, C Guillerey, K Kos, K Stannard, K Miles, RB Delconte, K Takeda, SE Nicholson, ND Huntington, MJ Smyth
OncoImmunology 2017
A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express α-gal epitopes
K Furukawa, M Tanemura, E Miyoshi, H Eguchi, H Nagano, K Matsunami, S Nagaoka, D Yamada, T Asaoka, T Noda, H Wada, K Kawamoto, K Goto, K Taniyama, M Mori, Y Doki, I Rooman
PloS one 2017
Targeting natural killer cells in cancer immunotherapy
C Guillerey, ND Huntington, MJ Smyth
Nature Immunology 2016
Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma
RE Cooke, NA Gherardin, SJ Harrison, H Quach, DI Godfrey, M Prince, R Koldej, DS Ritchie
Journal of Translational Medicine 2016
MGUS to myeloma: a mysterious gammopathy of underexplored significance
MV Dhodapkar
Blood 2016
Immunosurveillance and immunotherapy of tumors by innate immune cells
A Iannello, TW Thompson, M Ardolino, A Marcus, DH Raulet
Current Opinion in Immunology 2016
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia
M Boyiadzis, MR Bishop, R Abonour, KC Anderson, SM Ansell, D Avigan, L Barbarotta, AJ Barrett, KV Besien, PL Bergsagel, I Borrello, J Brody, J Brufsky, M Cairo, A Chari, A Cohen, J Cortes, SJ Forman, JW Friedberg, EJ Fuchs, SD Gore, S Jagannath, BS Kahl, J Kline, JN Kochenderfer, LW Kwak, R Levy, M Lima, MR Litzow, A Mahindra, J Miller, NC Munshi, RZ Orlowski, JM Pagel, DL Porter, SJ Russell, K Schwartz, MA Shipp, D Siegel, RM Stone, MS Tallman, JM Timmerman, FV Rhee, EK Waller, A Welsh, M Werner, PH Wiernik, MV Dhodapkar
Journal for ImmunoTherapy of Cancer 2016
Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies
C Guillerey, K Nakamura, S Vuckovic, GR Hill, MJ Smyth
Cellular and Molecular Life Sciences 2016
Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay
MP Abruzzese, MT Bilotta, C Fionda, A Zingoni, A Soriani, E Vulpis, C Borrelli, B Zitti, MT Petrucci, MR Ricciardi, R Molfetta, R Paolini, A Santoni, M Cippitelli
Journal of Hematology & Oncology 2016
Combination cancer immunotherapy and new immunomodulatory targets
KM Mahoney, PD Rennert, GJ Freeman
Nature Reviews Drug Discovery 2015
Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow
R Bam, S Khan, W Ling, SS Randal, X Li, B Barlogie, R Edmondson, S Yaccoby
BMC Cancer 2015
Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression
M Giuliani, B Janji, G Berchem
Oncotarget 2015
The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma
C Fionda, MP Abruzzese, A Zingoni, F Cecere, E Vulpis, G Peruzzi, A Soriani, R Molfetta, R Paolini, MR Ricciardi, MT Petrucci, A Santoni, M Cippitelli
Oncotarget 2015

← Previous 1 2 3 4 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Blogged by 1
Posted by 8 X users
Referenced in 12 patents
Mentioned by 1 peer review sites
On 1 Facebook pages
Referenced in 1 Wikipedia pages
Highlighted by 1 platforms
160 readers on Mendeley
See more details